JUNS
HEALTHCAREJupiter Neurosciences Inc
$0.36+0.00 (+0.67%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving JUNS Today?
No stock-specific AI insight has been generated for JUNS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.31$3.33
$0.36
Fundamentals
Market Cap$13M
P/E Ratio—
EPS$-0.25
Dividend Yield—
Dividend / Share—
ROE-7.4%
Profit Margin—
Debt / Equity—
Trading
Volume97K
Avg Volume (10D)—
Shares Outstanding36.3M
JUNS News
20 articles- Jupiter Neurosciences, Inc. to Present at The Market Movers Investor SummitYahoo Finance·May 4, 2026
- Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14Yahoo Finance·Apr 14, 2026
- Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory BoardYahoo Finance·Apr 7, 2026
- Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live streamYahoo Finance·Apr 1, 2026
- Jupiter Neurosciences to Present at Emerging Growth Conference on April 2Yahoo Finance·Mar 31, 2026
- Life Sciences Virtual Investor Forum Presentations Now Available for Online ViewingYahoo Finance·Mar 13, 2026
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thYahoo Finance·Mar 10, 2026
- Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026Yahoo Finance·Mar 2, 2026
- Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-LagoYahoo Finance·Feb 25, 2026
- Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial ExecutionYahoo Finance·Feb 23, 2026
- Jupiter Neurosciences Selected as B2i Digital Featured CompanyYahoo Finance·Feb 12, 2026
- Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 UsersYahoo Finance·Jan 28, 2026
- Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery ConferenceYahoo Finance·Jan 27, 2026
- Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6Yahoo Finance·Dec 23, 2025
- $50B+ Longevity Opportunity: Jupiter Neurosciences CEO Christer Rosen & President Alison Silva, Live at NasdaqYahoo Finance·Dec 10, 2025
- Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial MomentumYahoo Finance·Dec 3, 2025
- Jupiter Neurosciences to Participate in NobleCon21Yahoo Finance·Dec 2, 2025
- Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s DiseaseYahoo Finance·Nov 5, 2025
- Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible FinancingYahoo Finance·Oct 27, 2025
- Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand AmbassadorYahoo Finance·Sep 15, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$0.36
Day High$0.00
Day Low$0.00
52 Week High$3.33
52 Week Low$0.31
52-Week Range
$0.31$3.33
$0.36
Fundamentals
Market Cap$13M
P/E Ratio—
EPS$-0.25
Dividend Yield—
Dividend / Share—
ROE-7.4%
Profit Margin—
Debt / Equity—
Trading
Volume97K
Avg Volume (10D)—
Shares Outstanding36.3M
About Jupiter Neurosciences Inc
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. The company is headquartered in Jupiter, Florida.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—